CAS 147489 06 3 Pitavastatin Intermediates 99.0% min cGMP C32H36FNO4

CAS No . : 147489-06-3 Pitavastatin Intermediae 

Chemical Name : ( 4R,6S ) - 6 - ( ( 1E ) - 2 - ( cyclopropyl - 4 - ( 4-fluorophenyl ) - 3 - quinolinyl ) ethenyl ) - 2,2 - dimethyl- 1,3 - dioxane - 4 - acetic acid tert-butyl ester

CAS No . : 147489-06-3

Synonyms : ( 3R , 5S , 6E ) - 7 - [  2 - cyclopropyl - 4 - ( 4 - fluorophenyl ) - 3 - quinolyl ] -2,2 - dimethylethyl - 1,3 - dioxane - 6 - heptenoic acid , 1,1 - dimethylethyl ester 

Molecular Formula : C32H36FNO4

Molecular Weight : 517.637

Usage : Pitavastatin Intermediate 

Description: Pitavastatin Calcium is the active pharmaceutical ingredient (API) of branded drug Livalo. It was innovated by the Japanese company Nissan Chemical Industries and later Kowa Pharmaceuticals further develop Pitavastatin Calcium. So it was firstly launched in Janan in 2003 and also being marketed in India and South Korea. FDA approved Pitavastatin Calcium in 2009. The UK authority Medicines and Healthcare products Regulatory Agency, also called MHRA, approved it in 2010. Pitavastatin was also previously known as itabavastatin, itavastatin or nisvastatin.

( 4R,6S ) - 6 - ( ( 1E ) - 2 - ( cyclopropyl - 4 - ( 4-fluorophenyl ) - 3 - quinolinyl ) ethenyl ) - 2,2 - dimethyl- 1,3 - dioxane - 4 - acetic acid tert-butyl ester CAS No . : 147489-06-3 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.